

C1 1. Modified TNF, comprising TNF covalently bound to between about five and twelve PEG molecules having an approximate weight average molecular weight in the range of 10,000 to about 40,000.

C2 14. A method of enhancing the circulating half life of TNF while reducing its toxicity comprising modifying said TNF by covalently bonding to it between about five and twelve PEG molecules having an approximate weight average molecular weight in the range of 10,000 to about 40,000.

Please cancel claims 9 to 13 and 18 to 23.

REMARKS

Claims 1 to 24 are pending in the application. Claims 9 to 13 and 18 to 23 have been cancelled as drawn to a non-elected invention. Claims 1 and 14 have been amended, herein. No new claims have been added. Because the amendments remove issues for appeal, Applicant respectfully requests entry thereof. M.P.E.P. § 714.13.

Applicant respectfully requests reconsideration of the rejections of record in view of the foregoing amendments and the following remarks.

I. Alleged Anticipation

Claims 1 to 7 and 14 to 17 have been rejected under 35 U.S.C. § 102(b) as allegedly anticipated by Tsutsumi, Y., *et al.*, *Jpn J Cancer Res* 85:9-12 (1994)(hereinafter "the